Menopause in multiple sclerosis: Therapeutic considerations

Journal of Neurology

Volumn 261, Issue 7, 2014, Pages 1257-1268

  Bove, Riley ^a,b   Chitnis, Tanuja ^a,b   Houtchens, Maria ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Estrogen; Fatigue; Hormone replacement therapy; Multiple sclerosis; Osteoporosis; Sexual function

Indexed keywords

ESTROGEN;

BLADDER DYSFUNCTION; CANCER SCREENING; CLIMACTERIUM; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; ESTROGEN THERAPY; FATIGUE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INSOMNIA; MENOPAUSAL SYNDROME; MENOPAUSE; MOOD DISORDER; MULTIPLE SCLEROSIS; OSTEOPOROSIS; PAIN; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SLEEP DISORDER; SYMPTOMATOLOGY; FEMALE; PATHOPHYSIOLOGY; PHYSIOLOGY; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MULTIPLE SCLEROSIS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 84904876076     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7131-8     Document Type: Review

References (84)

1. Paty DW, Noseworthy JH, Ebers GC (1997) Diagnosis of multiple sclerosis. In: Paty DW, Ebers GC (eds) Multiple sclerosis. FA Davis Company, Philadelphia, pp 48-51
2. Bove R, Secor E, Healy BC, Musallam A, Vaughan T, Glanz BI, Greeke E, Weiner HL, Chitnis T, Wicks P, De Jager PL (2013) Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One 8(3):e59707. doi: 10.1371/journal.pone.0059707
3. Kato I, Toniolo P, Akhmedkhanov A, Koenig KL, Shore R, Zeleniuch-Jacquotte A (1998) Prospective study of factors influencing the onset of natural menopause. J Clin Epidemiol 51(12):1271-1276
4. Jacobsen BK, Heuch I, Kvale G (2003) Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol 157(10):923-929
5. Stolk L, Perry JR, Chasman DI, He C, Mangino M, Sulem P, Barbalic M, Broer L, Byrne EM, Ernst F, Esko T, Franceschini N, Gudbjartsson DF, Hottenga JJ, Kraft P, McArdle PF, Porcu E, Shin SY, Smith AV, van Wingerden S, Zhai G, Zhuang WV, Albrecht E, Alizadeh BZ, Aspelund T, Bandinelli S, Lauc LB, Beckmann JS, Boban M, Boerwinkle E, Broekmans FJ, Burri A, Campbell H, Chanock SJ, Chen C, Cornelis MC, Corre T, Coviello AD, d'Adamo P, Davies G, de Faire U, de Geus EJ, Deary IJ, Dedoussis GV, Deloukas P, Ebrahim S, Eiriksdottir G, Emilsson V, Eriksson JG, Fauser BC, Ferreli L, Ferrucci L, Fischer K, Folsom AR, Garcia ME, Gasparini P, Gieger C, Glazer N, Grobbee DE, Hall P, Haller T, Hankinson SE, Hass M, Hayward C, Heath AC, Hofman A, Ingelsson E, Janssens AC, Johnson AD, Karasik D, Kardia SL, Keyzer J, Kiel DP, Kolcic I, Kutalik Z, Lahti J, Lai S, Laisk T, Laven JS, Lawlor DA, Liu J, Lopez LM, Louwers YV, Magnusson PK, Marongiu M, Martin NG, Klaric IM, Masciullo C, McKnight B, Medland SE, Melzer D, Mooser V, Navarro P, Newman AB, Nyholt DR, Onland-Moret NC, Palotie A, Pare G, Parker AN, Pedersen NL, Peeters PH, Pistis G, Plump AS, Polasek O, Pop VJ, Psaty BM, Raikkonen K, Rehnberg E, Rotter JI, Rudan I, Sala C, Salumets A, Scuteri A, Singleton A, Smith JA, Snieder H, Soranzo N, Stacey SN, Starr JM, Stathopoulou MG, Stirrups K, Stolk RP, Styrkarsdottir U, Sun YV, Tenesa A, Thorand B, Toniolo D, Tryggvadottir L, Tsui K, Ulivi S, van Dam RM, van der Schouw YT, van Gils CH, van Nierop P, Vink JM, Visscher PM, Voorhuis M, Waeber G, Wallaschofski H, Wichmann HE, Widen E, Wijnands-van Gent CJ, Willemsen G, Wilson JF, Wolffenbuttel BH, Wright AF, Yerges-Armstrong LM, Zemunik T, Zgaga L, Zillikens MC, Zygmunt M, Study TL, Arnold AM, Boomsma DI, Buring JE, Crisponi L, Demerath EW, Gudnason V, Harris TB, Hu FB, Hunter DJ, Launer LJ, Metspalu A, Montgomery GW, Oostra BA, Ridker PM, Sanna S, Schlessinger D, Spector TD, Stefansson K, Streeten EA, Thorsteinsdottir U, Uda M, Uitterlinden AG, van Duijn CM, Volzke H, Murray A, Murabito JM, Visser JA, Lunetta KL (2012) Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet. doi: 10.1038/ng.1051
6. Gudmundsdottir SL, Flanders WD, Augestad LB (2012) Physical activity and age at menopause: the Nord-Trondelag population-based health study. Climacteric. doi: 10.3109/13697137.2011.646344
7. van Asselt KM, Kok HS, van Der Schouw YT, Grobbee DE, te Velde ER, Pearson PL, Peeters PH (2004) Current smoking at menopause rather than duration determines the onset of natural menopause. Epidemiology 15(5):634-639
8. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ (2012) Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 97(4):1159-1168. doi: 10.1210/jc.2011-3362
9. Vilar-Gonzalez S, Perez-Rozos A, Cabanillas-Farpon R (2011) Mechanism of hot flashes. Clin Transl Oncol 13(3):143-147. doi: 10.1007/s12094-011-0633-x
10. Ornat L, Martinez-Dearth R, Munoz A, Franco P, Alonso B, Tajada M, Perez-Lopez FR (2013) Sexual function, satisfaction with life and menopausal symptoms in middle-aged women. Maturitas 75(3):261-269. doi: 10.1016/j.maturitas.2013.04.007
11. Weber MT, Maki PM, McDermott MP (2013) Cognition and mood in perimenopause: a systematic review and meta-analysis. J Steroid Biochem Mol Biol. doi: 10.1016/j.jsbmb.2013.06.001
12. Gjelsvik B, Rosvold EO, Straand J, Dalen I, Hunskaar S (2011) Symptom prevalence during menopause and factors associated with symptoms and menopausal age. Results from the Norwegian Hordaland Women's Cohort study. Maturitas 70(4):383-390. doi: 10.1016/j.maturitas.2011.09.011
13. Sievert LL, Obermeyer CM (2012) Symptom clusters at midlife: a four-country comparison of checklist and qualitative responses. Menopause 19(2):133-144. doi: 10.1097/gme.0b013e3182292af3
14. Tintore M, Arrambide G (2009) Early onset multiple sclerosis: the role of gender. J Neurol Sci 286(1-2):31-34. doi: 10.1016/j.jns.2009.07.016
15. Chitnis T (2013) Role of puberty in multiple sclerosis risk and course. Clin Immunol. doi: 10.1016/j.clim.2013.03.014
16. Ramagopalan SV, Valdar W, Criscuoli M, DeLuca GC, Dyment DA, Orton SM, Yee IM, Ebers GC, Sadovnick AD (2009) Age of puberty and the risk of multiple sclerosis: a population based study. Eur J Neurol 16(3):342-347. doi: 10.1111/j.1468-1331.2008.02431.x
17. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 339(5):285-291. doi: 10.1056/ NEJM199807303390501
18. Sicotte NL, Liva SM, Klutch R, Pfeiffer P, Bouvier S, Odesa S, Wu TC, Voskuhl RR (2002) Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 52(4):421-428. doi: 10.1002/ana.10301
19. Mowry EM, Pesic M, Grimes B, Deen S, Bacchetti P, Waubant E (2009) Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology 72(7):602-608. doi: 10.1212/01.wnl.0000342458.39625.91
20. Damasceno A, Von Glehn F, Brandao CO, Damasceno BP, Cendes F (2012) Prognostic indicators for long-term disability in multiple sclerosis patients. J Neurol Sci. doi: 10.1016/j.jns.2012.09.020
21. Schoonheim MM, Popescu V, Rueda Lopes FC, Wiebenga OT, Vrenken H, Douw L, Polman CH, Geurts JJ, Barkhof F (2012) Subcortical atrophy and cognition: sex effects in multiple sclerosis. Neurology 79(17):1754-1761. doi: 10.1212/WNL.0b013e3182703f46
22. Confavreux C, Vukusic S (2006) Age at disability milestones in multiple sclerosis. Brain 129(Pt 3):595-605. doi: 10.1093/brain/awh714
23. Koch M, Kingwell E, Rieckmann P, Tremlett H (2010) The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 81(9):1039-1043. doi: 10.1136/jnnp.2010.208173
24. Bove R, Healy B, Augusting A, Musallam T, Gholipour T, Chitnis T (2012) Effect of gender on late-onset multiple sclerosis. Mult Scler J (in press)
25. Hooge JP, Redekop WK (1992) Multiple sclerosis with very late onset. Neurology 42(10):1907-1910
26. Kis B, Rumberg B, Berlit P (2008) Clinical characteristics of patients with late-onset multiple sclerosis. J Neurol 255(5):697-702. doi: 10.1007/s00415-008-0778-x
27. Tremlett H, Devonshire V (2006) Is late-onset multiple sclerosis associated with a worse outcome? Neurology 67(6):954-959. doi: 10.1212/01.wnl.0000237475.01655.9d
28. Noseworthy J, Paty D, Wonnacott T, Feasby T, Ebers G (1983) Multiple sclerosis after age 50. Neurology 33(12):1537-1544
29. Bove RM, Healy B, Augustine A, Musallam A, Gholipour T, Chitnis T (2012) Effect of gender on late-onset multiple sclerosis. Mult Scler. doi: 10.1177/1352458512438236
30. Filippi M, Wolinsky JS, Sormani MP, Comi G (2001) Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis. Neurology 56(3):422-423
31. Bove R, Musallam A, Healy B, Houtchens M, Glanz B, Khoury S, Guttmann C, De Jager P, Chitnis T (2013) No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. Manuscript under review Abstract presented at 2012 AAN conference, New Orleans AAN12PS1.P06.183
32. Mitchell AJ, Benito-Leon J, Gonzalez JM, Rivera-Navarro J (2005) Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 4(9):556-566. doi: 10.1016/S1474-4422(05)70166-6
33. Nortvedt MW, Riise T (2003) The use of quality of life measures in multiple sclerosis research. Mult Scler 9(1):63-72
34. Holmqvist P, Wallberg M, Hammar M, Landtblom AM, Brynhildsen J (2006) Symptoms of multiple sclerosis in women in relation to sex steroid exposure. Maturitas 54(2):149-153. doi: 10.1016/j.maturitas.2005.10.003
35. Smith R, Studd JW (1992) A pilot study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and the menstrual cycle. J R Soc Med 85(10):612-613
36. Wundes A, Amtmann D, Brown T, Christian S (2011) Menopause in women with multiple sclerosis. Int J MS Care 13(Supplement 3):47
37. Bove RM (2013) Autoimmune diseases and reproductive aging. Clinical immunology (special issue: sex influences in autoimmune disease). doi: 10.1016/j.clim.2013.02.010
38. Weiskopf D, Weinberger B, Grubeck-Loebenstein B (2009) The aging of the immune system. Transpl Int 22(11):1041-1050. doi: 10.1111/j.1432-2277.2009. 00927.x
39. Boulware MI, Kent BA, Frick KM (2011) The impact of age-related ovarian hormone loss on cognitive and neural function. Curr Top Behav Neurosci. doi: 10.1007/7854-2011-122
40. Rocca WA, Grossardt BR, Shuster LT (2011) Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res 1379:188-198. doi: 10.1016/j.brainres.2010.10.031
41. Ghezzi A, Annovazzi P, Portaccio E, Cesari E, Amato MP (2013) Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Rev Clin Immunol 9(7):683-692. doi: 10.1586/1744666X.2013.811046
42. Harward LE, Mitchell K, Pieper C, Copland S, Criscione-Schreiber LG, Clowse ME (2013) The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus 22(1):81-86. doi: 10.1177/ 0961203312468624
43. Cocco E, Sardu C, Gallo P, Capra R, Amato MP, Trojano M, Uccelli A, Marrosu MG (2008) Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler 14(9):1225-1233. doi: 10.1177/1352458508094882
44. Warnecke E (2011) What works? Evidence for lifestyle and nonprescription therapies in menopause. Aust Fam Physician 40(5):286-289
45. Medicine NCfCaA Menopausal Symptoms and Complementary Health Practices
46. Ghajarzadeh M, Jalilian R, Eskandari G, Sahraian MA, Azimi A, Mohammadifar M (2013) Fatigue in multiple sclerosis: relationship with disease duration, physical disability, disease pattern, age and sex. Acta Neurol Belg. doi: 10.1007/s13760-013-0198-2
47. Induruwa I, Constantinescu CS, Gran B (2012) Fatigue in multiple sclerosis - a brief review. J Neurol Sci 323(1-2):9-15. doi: 10.1016/j.jns.2012.08.007
48. Foley FW (2011) Assessment and treatment of sexual dysfunction in multiple sclerosis. In: Giesser BS (ed) Primer on multiple sclerosis. Oxford University Press, New York, pp 211-220
49. Ben-Zacharia AB (2011) Therapeutics for multiple sclerosis symptoms. Mt Sinai J Med 78(2):176-191. doi: 10.1002/msj.20245
50. Chwastiak LA, Ehde DM (2007) Psychiatric issues in multiple sclerosis. Psychiatr Clin North Am 30(4):803-817. doi: 10.1016/j.psc.2007.07.003
51. Gobbi C, Rocca M, Riccitelli G, Pagani E, Messina R, Preziosa P, Colombo B, Rodegher M, Falini A, Comi G, Filippi M (2013) Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. Mult Scler. doi: 10.1177/1352458513493684
52. Bonavita S, Tedeschi G, Gallo A (2013) Morphostructural MRI abnormalities related to neuropsychiatric disorders associated to multiple sclerosis. Mult Scler Int 2013:102454. doi: 10.1155/2013/102454
53. Skokou M, Soubasi E, Gourzis P (2012) Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations. ISRN Neurol 2012:427102. doi: 10.5402/2012/427102
54. Borghi M, Cavallo M, Carletto S, Ostacoli L, Zuffranieri M, Picci RL, Scavelli F, Johnston H, Furlan PM, Bertolotto A, Malucchi S (2013) Presence and significant determinants of cognitive impairment in a large sample of patients with multiple sclerosis. PLoS One 8(7):e69820. doi: 10.1371/journal.pone.0069820
55. Hanssen KT, Beiske AG, Landro NI, Hessen E (2013) Predictors of executive complaints and executive deficits in multiple sclerosis. Acta Neurol Scand. doi: 10.1111/ane.12177
56. Mohammadi K, Rahnama P, Moayed Mohseni S, Sahraian MA, Montazeri A (2013) Determinants of sexual dysfunction in women with multiple sclerosis. BMC Neurol 13(1):83. doi: 10.1186/1471-2377-13-83
57. Harsh V, Meltzer-Brody S, Rubinow DR, Schmidt PJ (2009) Reproductive aging, sex steroids, and mood disorders. Harv Rev Psychiatry 17(2):87-102. doi: 10.1080/10673220902891877
58. Weber MT, Rubin LH, Maki PM (2013) Cognition in perimenopause: the effect of transition stage. Menopause 20(5):511-517. doi: 10.1097/GME.0b013e31827655e5
59. Hall E, Frey BN, Soares CN (2011) Non-hormonal treatment strategies for vasomotor symptoms: a critical review. Drugs 71(3):287-304. doi: 10.2165/11585360-000000000-00000
60. Kravitz HM, Joffe H (2011) Sleep during the perimenopause: a SWAN story. Obstet Gynecol Clin North Am 38(3):567-586. doi: 10.1016/j.ogc.2011.06.002
61. Dugan SA, Powell LH, Kravitz HM, Everson Rose SA, Karavolos K, Luborsky J (2006) Musculoskeletal pain and menopausal status. Clin J Pain 22(4):325-331. doi: 10.1097/01.ajp.0000208249.07949.d5
62. Alexander JL, Dennerstein L, Woods NF, Halbreich U, Kotz K, Richardson G, Graziottin A, Sherman JJ (2007) Arthralgias, bodily aches and pains and somatic complaints in midlife women: etiology, pathophysiology and differential diagnosis. Expert Rev Neurother 7(11 Suppl):S15-S26. doi: 10.1586/14737175.7. 11s.S15
63. Magliano M (2010) Menopausal arthralgia: fact or fiction. Maturitas 67(1):29-33. doi: 10.1016/j.maturitas.2010.04.009
64. MacGregor EA (2012) Perimenopausal migraine in women with vasomotor symptoms. Maturitas 71(1):79-82. doi: 10.1016/j.maturitas.2011.11.001
65. Koch M, Uyttenboogaart M, Polman S, De Keyser J (2008) Seizures in multiple sclerosis. Epilepsia 49(6):948-953. doi: 10.1111/j.1528-1167.2008. 01565.x
66. Erel T, Guralp O (2011) Epilepsy and menopause. Arch Gynecol Obstet 284(3):749-755. doi: 10.1007/s00404-011-1936-4
67. Palomba S, Di Cello A, Riccio E, Manguso F, La Sala GB (2011) Ovarian function and gastrointestinal motor activity. Minerva Endocrinol 36(4):295-310
68. North American Menopause Society (2012) The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 19(3):257-271. doi: 10.1097/gme.0b013e31824b970a
69. Henderson VW (2013) Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol. doi: 10.1016/j.jsbmb.2013.05.010
70. Craig MC, Maki PM, Murphy DG (2005) The Women's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol 4(3):190-194. doi: 10.1016/S1474-4422(05)01016-1
71. Leib ES, Saag KG, Adachi JD, Geusens PP, Binkley N, McCloskey EV, Hans DB (2011) Official positions for FRAX((R)) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX((R)) of the 10 years risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX((R)). J Clin Densitom 14(3):212-219. doi: 10.1016/j.jocd.2011.05.014
72. Sammaritano LR (2012) Menopause in patients with autoimmune diseases. Autoimmun Rev 11(6-7):A430-A436. doi: 10.1016/j.autrev.2011.11.006
73. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society (2010). Menopause 17(1):25-54; quiz 55-26. doi: 10.1097/gme.0b013e3181c617e6
74. Christenson ES, Jiang X, Kagan R, Schnatz P (2012) Osteoporosis management in post-menopausal women. Minerva Ginecol 64(3):181-194
75. Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J, Tremlett H (2012) Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry 83(1):61-66. doi: 10.1136/jnnp-2011-300616
76. Sabuncu MR, Buckner RL, Smoller JW, Lee PH, Fischl B, Sperling RA (2012) The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. Cereb Cortex 22(11):2653-2661. doi: 10.1093/cercor/bhr348
77. Sadovnick AD, Eisen K, Ebers GC, Paty DW (1991) Cause of death in patients attending multiple sclerosis clinics. Neurology 41(8):1193-1196
78. Tabares-Seisdedos R, Dumont N, Baudot A, Valderas JM, Climent J, Valencia A, Crespo-Facorro B, Vieta E, Gomez-Beneyto M, Martinez S, Rubenstein JL (2011) No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol 12(6):604-608. doi: 10.1016/S1470-2045(11)70041-9
79. Alhasso A, Glazener CM, Pickard R, N'Dow J (2005) Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev (3):CD001842. doi: 10.1002/14651858.CD001842.pub2
80. Firth N (2013) Effectiveness of psychologically focused group interventions for multiple sclerosis: a review of the experimental literature. J Health Psychol. doi: 10.1177/1359105313479630
81. Sun Z, Hao Y, Zhang M (2013) Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecol Obstet Invest 75(4):255-262. doi: 10.1159/000348564
82. Umland EM, Falconieri L (2012) Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine. Int J Womens Health 4:305-319. doi: 10.2147/IJWH.S24614
83. Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ (2013) Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause 20(3):291-298. doi: 10.1097/GME.0b013e31826ce3ed
84. Foley F (2009) Talking about sexual dysfunction. In: Kalb R (ed) National Multiple Sclerosis Society Patient Resource Center Pamphlet. http://www.nationalmssociety.org/download.aspx?id=175